<DOC>
	<DOCNO>NCT00002378</DOCNO>
	<brief_summary>To determine proportion patient whose plasma HIV-1 RNA level fall level detection ( &lt; 400 copies/ml ) week 24 study therapy . To determine absolute change plasma HIV-1 RNA 24 week study treatment . To collect safety data treatment regimen . AS PER AMENDMENT 12/12/97 : To compare virologic response Fortovase ( FTV ) ( Saquinavir ) Soft Gel Capsule ( SGC ) tid plus nucleoside reverse transcriptase inhibitor ( NRTIs ) versus FTV bid plus NRTIs . Further , compare virologic response FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus NRTI respect : percentage patient whose plasma HIV-1 RNA level fall Amplicor assay level detection ( &lt; 400 copies/ml ) week 24 week 48 .</brief_summary>
	<brief_title>A Comparison Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used HIV-1 Infected Patients</brief_title>
	<detailed_description>Patients randomize receive 1 3 study regimen : Group A - Saquinavir ( SQV ) sgc plus 2 new reverse transcriptase inhibitor ( RTIs ) , Group B - SQV sgc plus delavirdine plus new RTI , Group C - SQV sgc plus nelfinavir plus new RTI , SQV sgc plus ritonavir plus 2 new RTIs . NOTE : `` New RTI '' define study reverse transcriptase inhibitor patient never expose . AS PER AMENDMENT 12/12/97 : In open-label , multicenter , Phase IIIB , comparative study , 825 patient randomized treatment arm . ( NOTE : 50 % patient treatment naive 50 % NRTI experienced . ) Further , patient randomize stratification base HIV-1 RNA level ( 5,000-30,000 copies/ml vs. great 30,000 copies/ml ) prior antiretroviral therapy one three study arm . The drug regimens three treatment arm follow : ARM A : Fortovase ( FTV ) , plus 2 new NRTIs* . ARM B : FTV plus 2 new NRTIs* . ARM C : FTV plus nelfinavir plus new NRTI** . - Naive patient Arm A Arm B take : d4T ( zidovudine ) plus 3TC unless contraindicate . ** Naive patient Arm C take : d4T , unless contraindicate . - NRTI experience patient Arms A &amp; B treat 2 NRTIs he/she previously expose . If patient 1 NRTI he/she never expose , second NRTI one patient previously expose distant past . Therapy administer initial 24 week may extend additional 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 infection . HIV RNA &gt; = 5000 copies/ml Amplicor assay . Signed , inform consent parent legal guardian patient le 18 year old . Prior Medication : Required : ( Note : 50 % patient treatment naive ) . &gt; 3 month cumulative therapy antiretrovirals nonnucleoside reverse transcriptase inhibitor and/or protease inhibitor . Stable antiretroviral therapy least 4 week prior enrollment . Allowed : &lt; = 2 week cumulative treatment protease inhibitor . AS PER AMENDMENT 12/12/97 : Required : NRTI experience patient : &gt; 3 month cumulative therapy antiretrovirals . &lt; = 2 week cumulative previous treatment nonnucleoside analogue reverse transcriptase inhibitor ( NNRTIs ) . &lt; = 2 week cumulative previous treatment protease inhibitor . Must least one NRTI ( preferably two ) he/she previously expose . Stable antiretroviral therapy define within ( +/ ) 1 log HIV1 RNA 2 recent value great 8 week apart ( may include screen visit ) prior study enrollment . ( NOTE : If patient previous HIV1 RNA value , screen accept . ) Required : Note : 50 % patient treatment naive 50 % NRTI experience . AS PER AMENDMENT 12/12/97 .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>